News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …
MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …
MacroGenics Inc (NASDAQ: MGNX) reported second-quarter earnings per share (EPS) of $-1.10, missing analyst estimates by $1.02, and revenue of $32.83M, which fell short of the consensus estimate of $59.14M. The company's stock has seen significant volatility, being down 4.00% in the last three …
MacroGenics (NASDAQ: MGNX) reported a Q2 2026 adjusted EPS of $(0.27), significantly missing the $(0.13) estimate, and revenue of $32.832 million, falling short of the $67.456 million forecast despite a 47.62% YoY increase. The company posted a net income of $19.5 million, a turnaround …
MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …
* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …
MacroGenics Inc. (MGNX) reported second-quarter earnings of $19.5 million, or 31 cents per share, significantly exceeding Wall Street's expectation of a 40-cent loss per share. However, the biopharmaceutical company's revenue of $32.8 million fell short of the $44 million forecast by analysts. The earnings …
Wasatch Advisors LP significantly increased its stake in MacroGenics (NASDAQ:MGNX) during the second quarter, purchasing an additional 459,180 shares to bring its total ownership to over 2 million shares, valued at approximately $9.3 million. This increase means Wasatch Advisors now owns 3.18% of the …
Genius Sports Limited (NYSE:GENI) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $11.44, significantly above its current opening price of $7.74. The company reported strong year-over-year revenue growth of 64.7% to $195.5 million, surpassing estimates, although …
Genius Sports (GENI) reported second-quarter 2026 results with sales of US$195.5 million and a wider net loss of US$76.73 million, but raised its full-year 2026 revenue outlook to over US$1 billion. The company also announced strategic partnerships with Kalshi and Polymarket to integrate its …
Soligenix, Inc. (NASDAQ: SNGX) is applying for funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of a vaccine against the Bundibugyo virus, in collaboration with Dr. Axel Lehrer. The application will leverage previous work on bivalent and trivalent thermostable vaccines …
MacroGenics, Inc. announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program, triggering a $10 million payment to MacroGenics. This program incorporates MacroGenics’ TRIDENT® platform and targets solid tumors. MacroGenics remains eligible for up to …
MacroGenics Inc. shares rose 4.3% after Gilead Sciences exercised its option on a preclinical bispecific program, resulting in a $10 million payment to MacroGenics. This exercise is part of a 2022 collaboration agreement, under which MacroGenics could receive up to $1.6 billion in additional …
Northland Securities has cut its Q3 2026 EPS estimate for Genius Sports (NYSE: GENI) to a loss of $0.04 per share, down from a previous estimate of a $0.03 profit. This adjustment comes after Genius Sports reported a Q2 EPS of negative $0.28, missing …
Wall Street Zen has downgraded Genius Sports (NYSE:GENI) from "sell" to "strong sell," despite MarketBeat's consensus "Moderate Buy" rating and $11.44 price target. Genius Sports reported higher-than-expected quarterly revenue of $195.5 million, a 64.7% year-over-year increase, but its adjusted loss of $0.28 per share …
The article discusses the recent bullish sentiment from analysts towards Genius Sports Limited (NYSE:GENI) following its latest financial results. It suggests that analysts have become more optimistic about the company's stock, likely due to strong performance or positive future outlook indicated by the results. …
This article provides an analysis of Genie Energy Ltd. Class B Stock (NYSE: GNE) based on AI-generated technical signals. It highlights a near-term strong sentiment with neutral mid and long-term outlooks, identifying a significant short setup. The report details various institutional trading strategies, including …
MacroGenics Inc is projected to report a loss of 13 cents per share. This information is part of an earnings preview, indicating an upcoming financial announcement from the company. The full article is available through a subscription to TradingView.
Soligenix has ended the development of its topical cutaneous T-cell lymphoma (CTCL) therapy, HyBryte, after the drug failed to meet its primary goals in a Phase III trial. The company will now focus on its pipeline candidate, dusquetide, for Behçet's disease and developing commercial …
Genius Sports Limited (NYSE:GENI) saw its shares rise 7.4% after reporting quarterly results. While revenues of US$196m beat expectations, statutory losses per share increased to US$0.28. Analysts have a mixed view, with revenue estimates holding steady but loss per share expectations expanding, yet the …
Sharemaestro market context Trend signal started 52 weeks -34.9%Search by ticker symbol or company name and select a result to open its chart.